Kobayashi Pharmaceutical Co(JP:4967)
Â¥6,931.00-72.00 (-1.03%)
JP:4967
Kobayashi Pharmaceutical Co financials statements
Â¥6,931.00
At close:-72.00 (-1.03%)
Want to see JP:4967 full AI Analyst Report?
Kobayashi Pharmaceutical Co (4967) Ratios
0 Followers
Kobayashi Pharmaceutical Co Ratios
JP:4967's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, JP:4967's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.47 | 3.11 | 2.82 | 3.34 | 3.59 |
| Quick Ratio | 2.10 | 2.59 | 2.43 | 3.00 | 3.29 |
| Cash Ratio | 1.04 | 1.10 | 1.27 | 1.86 | 1.87 |
| Solvency Ratio | 0.19 | 0.35 | 0.42 | 0.44 | 0.43 |
| Operating Cash Flow Ratio | 0.43 | 0.24 | 0.33 | 0.62 | 0.44 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 48.44 | 122.28 | 22419.00 |
| Net Current Asset Value | ¥ 84.50B | ¥ 92.57B | ¥ 95.67B | ¥ 114.96B | ¥ 124.93B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.30 | 1.24 | 1.31 | 1.29 | 1.29 |
| Debt Service Coverage Ratio | 444.04 | 647.18 | 64.77 | 91.04 | 1293.11 |
| Interest Coverage Ratio | 532.96 | 887.86 | 888.97 | 1481.61 | 1448.06 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 9.50 | 11.76 | 13.40 | 10.50 | 8.29 |
| Net Debt to EBITDA | -4.92 | -2.28 | -2.10 | -2.86 | -2.91 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.11% | 52.90% | 55.56% | 55.53% | 57.18% |
| EBIT Margin | 2.28% | 8.42% | 15.90% | 16.82% | 17.81% |
| EBITDA Margin | 7.55% | 13.26% | 19.40% | 20.04% | 20.93% |
| Operating Profit Margin | 9.00% | 15.01% | 14.86% | 16.04% | 16.79% |
| Pretax Profit Margin | 2.26% | 8.40% | 15.89% | 16.81% | 17.80% |
| Net Profit Margin | 2.21% | 6.08% | 11.73% | 12.04% | 12.70% |
| Continuous Operations Profit Margin | 2.21% | 6.08% | 11.73% | 12.04% | 12.70% |
| Net Income Per EBT | 97.68% | 72.36% | 73.80% | 71.64% | 71.34% |
| EBT Per EBIT | 25.08% | 55.97% | 106.90% | 104.80% | 106.03% |
| Return on Assets (ROA) | 1.33% | 3.79% | 7.60% | 7.83% | 7.81% |
| Return on Equity (ROE) | 1.73% | 4.72% | 9.93% | 10.12% | 10.08% |
| Return on Capital Employed (ROCE) | 6.93% | 11.35% | 12.20% | 13.07% | 12.91% |
| Return on Invested Capital (ROIC) | 6.77% | 8.21% | 8.97% | 9.34% | 9.20% |
| Return on Tangible Assets | 1.42% | 4.11% | 8.27% | 8.26% | 8.22% |
| Earnings Yield | 0.91% | 2.17% | 3.95% | 2.88% | 2.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.18 | 3.35 | 3.27 | 3.47 | 2.82 |
| Payables Turnover | 5.44 | 5.31 | 8.81 | 8.17 | 7.15 |
| Inventory Turnover | 3.56 | 3.23 | 3.49 | 4.18 | 4.40 |
| Fixed Asset Turnover | 2.46 | 2.46 | 3.64 | 4.78 | 6.89 |
| Asset Turnover | 0.60 | 0.62 | 0.65 | 0.65 | 0.61 |
| Working Capital Turnover Ratio | 1.78 | 1.65 | 1.55 | 1.32 | 1.27 |
| Cash Conversion Cycle | 150.19 | 153.19 | 174.65 | 147.65 | 161.57 |
| Days of Sales Outstanding | 114.81 | 108.85 | 111.49 | 105.06 | 129.65 |
| Days of Inventory Outstanding | 102.49 | 113.07 | 104.56 | 87.28 | 82.95 |
| Days of Payables Outstanding | 67.11 | 68.73 | 41.41 | 44.69 | 51.02 |
| Operating Cycle | 217.30 | 221.92 | 216.06 | 192.34 | 212.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 344.24 | 151.28 | 242.08 | 413.81 | 286.96 |
| Free Cash Flow Per Share | 165.96 | -199.23 | 63.17 | 203.38 | 233.40 |
| Dividend Paid and CapEx Coverage Ratio | 1.22 | 0.34 | 0.88 | 1.40 | 2.15 |
| Capital Expenditure Coverage Ratio | 1.93 | 0.43 | 1.35 | 1.97 | 5.36 |
| Operating Cash Flow Coverage Ratio | 37.74 | 13.29 | 18.60 | 40.30 | 35.59 |
| Operating Cash Flow to Sales Ratio | 0.15 | 0.07 | 0.11 | 0.19 | 0.14 |
| Free Cash Flow Yield | 3.06% | -3.20% | 0.93% | 2.25% | 2.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 110.37 | 46.01 | 25.32 | 34.78 | 35.82 |
| Price-to-Sales (P/S) Ratio | 2.43 | 2.80 | 2.97 | 4.19 | 4.55 |
| Price-to-Book (P/B) Ratio | 1.91 | 2.17 | 2.51 | 3.52 | 3.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 32.71 | -31.27 | 107.49 | 44.40 | 38.73 |
| Price-to-Operating Cash Flow Ratio | 15.77 | 41.18 | 28.05 | 21.82 | 31.50 |
| Price-to-Earnings Growth (PEG) Ratio | -1.73 | -0.93 | 7.69 | 12.09 | 13.24 |
| Enterprise Value Multiple | 27.31 | 18.81 | 13.21 | 18.03 | 18.83 |
| Enterprise Value | 341.87B | 413.10B | 444.42B | 600.97B | 611.86B |
| EV to EBITDA | 27.31 | 18.81 | 13.21 | 18.03 | 18.83 |
| EV to Sales | 2.06 | 2.49 | 2.56 | 3.61 | 3.94 |
| EV to Free Cash Flow | 27.71 | -27.89 | 92.76 | 38.31 | 33.56 |
| EV to Operating Cash Flow | 13.36 | 36.73 | 24.21 | 18.83 | 27.29 |
| Tangible Book Value Per Share | 2604.28 | 2593.56 | 2415.57 | 2393.51 | 2341.64 |
| Shareholders’ Equity Per Share | 2838.37 | 2871.57 | 2700.56 | 2566.05 | 2503.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.28 | 0.26 | 0.28 | 0.29 |
| Revenue Per Share | 2229.57 | 2227.66 | 2287.06 | 2155.78 | 1987.23 |
| Net Income Per Share | 49.18 | 135.42 | 268.16 | 259.61 | 252.35 |
| Tax Burden | 0.98 | 0.72 | 0.74 | 0.72 | 0.71 |
| Interest Burden | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 |
| SG&A to Revenue | 0.33 | 0.29 | 0.17 | 0.03 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 7.00 | 1.12 | 0.90 | 1.14 | 0.81 |
Currency in JPY
